Figure 4

PKC inhibitor influences the effects of mGluR5 modulators on NMDA receptor activation and suppression. Pretreatment of hippocampal slices with chelerythrine (10 μM), a PKC inhibitor, inhibited the enhancing effects of DFB (10 μM), CHPG (50 μM), and CDPPB (10 μM) on NMDA-induced field potentials (a) and reversed the attenuating effects of mGluR5 modulators on ketamine (b, 10 μM) or D-APV (c, 50 μM)-evoked NMDA receptor suppression. All values are expressed as the mean ± S.E.M. (n = 5). Data were statistically analyzed by one-way ANOVA followed by a Student-Newman-Keuls post-hoc test.